ArticleCell death discovery2026
Salinomycin as a death switch: how gastric cancer cells choose their demise.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ITPRIPL1: A tumor immune-associated biomarker with prognostic and therapeutic implications in gastrointestinal cancer.Scientific reports · 2026Article
- Low KIF4A expression is associated with gastric cancer progression and aggressive phenotypes.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Gastric cancer (GC) remains a significant global health challenge due to the prevalence of multidrug resistance (MDR) that leads to therapy failure. MDR is driven by tumor heterogeneity and the presence of cancer stem cells (CSCs). Drug repurposing represents an innovative therapeutic strategy to overcome MDR. In this view, Salinomycin (Sal) has shown promising anticancer activity and selectivity against CSCs. Since its mechanisms in GC are not fully understood, we investigated its activity in a panel of four GC cell lines: SNU1, NCI-N87, AGS, and KATO-III. Our results demonstrate that Sal induces distinct forms of regulated cell death (RCD) in a cell line-specific manner. Sal treatment led to apoptosis in SNU1 and NCI-N87 cells, while it triggered ferroptosis in AGS and KATO-III cells. Autophagy was a common early event in all cell lines. Western blot analysis confirmed the activation of distinct signaling axes: mTOR/survivin/CASP-3/BAX in apoptotic cells and mTOR/survivin/SLC7A11/GPX4 in ferroptotic cells. Bioinformatics analysis revealed a unique 20-differentially expressed gene signature for ferroptosis-prone GC cells. Notably, Sal significantly reduced the proportion of CD44
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.